Cargando…

Identifying potential therapeutic targets of mulberry leaf extract for the treatment of type 2 diabetes: a TMT-based quantitative proteomic analysis

BACKGROUND: Mulberry (Morus alba L.) leaf, as a medicinal and food homologous traditional Chinese medicine, has a clear therapeutic effect on type 2 diabetes mellitus (T2DM), yet its underlying mechanisms have not been totally clarified. The study aimed to explore the mechanism of mulberry leaf in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Lu, Wang, Jingkang, He, Changhao, Huang, Yan, Fu, Wanxin, Zhang, Huilin, An, Yongcheng, Wang, Menglu, Shan, Ziyi, Li, Huimin, Lv, Yinglan, Wang, Chen, Cheng, Long, Dai, Hongyu, Duan, Yuhui, Zhao, Hongbin, Zhao, Baosheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476348/
https://www.ncbi.nlm.nih.gov/pubmed/37667364
http://dx.doi.org/10.1186/s12906-023-04140-3
_version_ 1785100910144258048
author Shi, Lu
Wang, Jingkang
He, Changhao
Huang, Yan
Fu, Wanxin
Zhang, Huilin
An, Yongcheng
Wang, Menglu
Shan, Ziyi
Li, Huimin
Lv, Yinglan
Wang, Chen
Cheng, Long
Dai, Hongyu
Duan, Yuhui
Zhao, Hongbin
Zhao, Baosheng
author_facet Shi, Lu
Wang, Jingkang
He, Changhao
Huang, Yan
Fu, Wanxin
Zhang, Huilin
An, Yongcheng
Wang, Menglu
Shan, Ziyi
Li, Huimin
Lv, Yinglan
Wang, Chen
Cheng, Long
Dai, Hongyu
Duan, Yuhui
Zhao, Hongbin
Zhao, Baosheng
author_sort Shi, Lu
collection PubMed
description BACKGROUND: Mulberry (Morus alba L.) leaf, as a medicinal and food homologous traditional Chinese medicine, has a clear therapeutic effect on type 2 diabetes mellitus (T2DM), yet its underlying mechanisms have not been totally clarified. The study aimed to explore the mechanism of mulberry leaf in the treatment of T2DM through tandem mass tag (TMT)—based quantitative proteomics analysis of skeletal muscle. METHODS: The anti-diabetic activity of mulberry leaf extract (MLE) was evaluated by using streptozotocin-induced diabetic rats at a dose of 4.0 g crude drug /kg p.o. daily for 8 weeks. Fasting blood glucose, body weight, food and water intake were monitored at specific intervals, and oral glucose tolerance test and insulin tolerance test were conducted at the 7th and 8th week respectively. At the end of the experiment, levels of glycated hemoglobin A1c, insulin, free fat acid, leptin, adiponectin, total cholesterol, triglyceride, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were assessed and the pathological changes of rat skeletal muscle were observed by HE staining. TMT-based quantitative proteomic analysis of skeletal muscle and bioinformatics analysis were performed and differentially expressed proteins (DEPs) were validated by western blot. The interactions between the components of MLE and DEPs were further assessed using molecular docking. RESULTS: After 8 weeks of MLE intervention, the clinical indications of T2DM such as body weight, food and water intake of rats were improved to a certain extent, while insulin sensitivity was increased and glycemic control was improved. Serum lipid profiles were significantly reduced, and the skeletal muscle fiber gap and atrophy were alleviated. Proteomic analysis of skeletal muscle showed that MLE treatment reversed 19 DEPs in T2DM rats, regulated cholesterol metabolism, fat digestion and absorption, vitamin digestion and absorption and ferroptosis signaling pathways. Key differential proteins Apolipoprotein A-1 (ApoA1) and ApoA4 were successfully validated by western blot and exhibited strong binding activity to the MLE’s ingredients. CONCLUSIONS: This study first provided skeletal muscle proteomic changes in T2DM rats before and after MLE treatment, which may help us understand the molecular mechanisms, and provide a foundation for developing potential therapeutic targets of anti-T2DM of MLE. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12906-023-04140-3.
format Online
Article
Text
id pubmed-10476348
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104763482023-09-05 Identifying potential therapeutic targets of mulberry leaf extract for the treatment of type 2 diabetes: a TMT-based quantitative proteomic analysis Shi, Lu Wang, Jingkang He, Changhao Huang, Yan Fu, Wanxin Zhang, Huilin An, Yongcheng Wang, Menglu Shan, Ziyi Li, Huimin Lv, Yinglan Wang, Chen Cheng, Long Dai, Hongyu Duan, Yuhui Zhao, Hongbin Zhao, Baosheng BMC Complement Med Ther Research BACKGROUND: Mulberry (Morus alba L.) leaf, as a medicinal and food homologous traditional Chinese medicine, has a clear therapeutic effect on type 2 diabetes mellitus (T2DM), yet its underlying mechanisms have not been totally clarified. The study aimed to explore the mechanism of mulberry leaf in the treatment of T2DM through tandem mass tag (TMT)—based quantitative proteomics analysis of skeletal muscle. METHODS: The anti-diabetic activity of mulberry leaf extract (MLE) was evaluated by using streptozotocin-induced diabetic rats at a dose of 4.0 g crude drug /kg p.o. daily for 8 weeks. Fasting blood glucose, body weight, food and water intake were monitored at specific intervals, and oral glucose tolerance test and insulin tolerance test were conducted at the 7th and 8th week respectively. At the end of the experiment, levels of glycated hemoglobin A1c, insulin, free fat acid, leptin, adiponectin, total cholesterol, triglyceride, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were assessed and the pathological changes of rat skeletal muscle were observed by HE staining. TMT-based quantitative proteomic analysis of skeletal muscle and bioinformatics analysis were performed and differentially expressed proteins (DEPs) were validated by western blot. The interactions between the components of MLE and DEPs were further assessed using molecular docking. RESULTS: After 8 weeks of MLE intervention, the clinical indications of T2DM such as body weight, food and water intake of rats were improved to a certain extent, while insulin sensitivity was increased and glycemic control was improved. Serum lipid profiles were significantly reduced, and the skeletal muscle fiber gap and atrophy were alleviated. Proteomic analysis of skeletal muscle showed that MLE treatment reversed 19 DEPs in T2DM rats, regulated cholesterol metabolism, fat digestion and absorption, vitamin digestion and absorption and ferroptosis signaling pathways. Key differential proteins Apolipoprotein A-1 (ApoA1) and ApoA4 were successfully validated by western blot and exhibited strong binding activity to the MLE’s ingredients. CONCLUSIONS: This study first provided skeletal muscle proteomic changes in T2DM rats before and after MLE treatment, which may help us understand the molecular mechanisms, and provide a foundation for developing potential therapeutic targets of anti-T2DM of MLE. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12906-023-04140-3. BioMed Central 2023-09-04 /pmc/articles/PMC10476348/ /pubmed/37667364 http://dx.doi.org/10.1186/s12906-023-04140-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Shi, Lu
Wang, Jingkang
He, Changhao
Huang, Yan
Fu, Wanxin
Zhang, Huilin
An, Yongcheng
Wang, Menglu
Shan, Ziyi
Li, Huimin
Lv, Yinglan
Wang, Chen
Cheng, Long
Dai, Hongyu
Duan, Yuhui
Zhao, Hongbin
Zhao, Baosheng
Identifying potential therapeutic targets of mulberry leaf extract for the treatment of type 2 diabetes: a TMT-based quantitative proteomic analysis
title Identifying potential therapeutic targets of mulberry leaf extract for the treatment of type 2 diabetes: a TMT-based quantitative proteomic analysis
title_full Identifying potential therapeutic targets of mulberry leaf extract for the treatment of type 2 diabetes: a TMT-based quantitative proteomic analysis
title_fullStr Identifying potential therapeutic targets of mulberry leaf extract for the treatment of type 2 diabetes: a TMT-based quantitative proteomic analysis
title_full_unstemmed Identifying potential therapeutic targets of mulberry leaf extract for the treatment of type 2 diabetes: a TMT-based quantitative proteomic analysis
title_short Identifying potential therapeutic targets of mulberry leaf extract for the treatment of type 2 diabetes: a TMT-based quantitative proteomic analysis
title_sort identifying potential therapeutic targets of mulberry leaf extract for the treatment of type 2 diabetes: a tmt-based quantitative proteomic analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476348/
https://www.ncbi.nlm.nih.gov/pubmed/37667364
http://dx.doi.org/10.1186/s12906-023-04140-3
work_keys_str_mv AT shilu identifyingpotentialtherapeutictargetsofmulberryleafextractforthetreatmentoftype2diabetesatmtbasedquantitativeproteomicanalysis
AT wangjingkang identifyingpotentialtherapeutictargetsofmulberryleafextractforthetreatmentoftype2diabetesatmtbasedquantitativeproteomicanalysis
AT hechanghao identifyingpotentialtherapeutictargetsofmulberryleafextractforthetreatmentoftype2diabetesatmtbasedquantitativeproteomicanalysis
AT huangyan identifyingpotentialtherapeutictargetsofmulberryleafextractforthetreatmentoftype2diabetesatmtbasedquantitativeproteomicanalysis
AT fuwanxin identifyingpotentialtherapeutictargetsofmulberryleafextractforthetreatmentoftype2diabetesatmtbasedquantitativeproteomicanalysis
AT zhanghuilin identifyingpotentialtherapeutictargetsofmulberryleafextractforthetreatmentoftype2diabetesatmtbasedquantitativeproteomicanalysis
AT anyongcheng identifyingpotentialtherapeutictargetsofmulberryleafextractforthetreatmentoftype2diabetesatmtbasedquantitativeproteomicanalysis
AT wangmenglu identifyingpotentialtherapeutictargetsofmulberryleafextractforthetreatmentoftype2diabetesatmtbasedquantitativeproteomicanalysis
AT shanziyi identifyingpotentialtherapeutictargetsofmulberryleafextractforthetreatmentoftype2diabetesatmtbasedquantitativeproteomicanalysis
AT lihuimin identifyingpotentialtherapeutictargetsofmulberryleafextractforthetreatmentoftype2diabetesatmtbasedquantitativeproteomicanalysis
AT lvyinglan identifyingpotentialtherapeutictargetsofmulberryleafextractforthetreatmentoftype2diabetesatmtbasedquantitativeproteomicanalysis
AT wangchen identifyingpotentialtherapeutictargetsofmulberryleafextractforthetreatmentoftype2diabetesatmtbasedquantitativeproteomicanalysis
AT chenglong identifyingpotentialtherapeutictargetsofmulberryleafextractforthetreatmentoftype2diabetesatmtbasedquantitativeproteomicanalysis
AT daihongyu identifyingpotentialtherapeutictargetsofmulberryleafextractforthetreatmentoftype2diabetesatmtbasedquantitativeproteomicanalysis
AT duanyuhui identifyingpotentialtherapeutictargetsofmulberryleafextractforthetreatmentoftype2diabetesatmtbasedquantitativeproteomicanalysis
AT zhaohongbin identifyingpotentialtherapeutictargetsofmulberryleafextractforthetreatmentoftype2diabetesatmtbasedquantitativeproteomicanalysis
AT zhaobaosheng identifyingpotentialtherapeutictargetsofmulberryleafextractforthetreatmentoftype2diabetesatmtbasedquantitativeproteomicanalysis